Durham, North Carolina-based Cell Microsystems announced its acquisition of Fluxion Biosciences. According to data captured in the LevinPro HC database, this acquisition represents the 102nd Biotechnology transaction of 2023, and 19th in the third quarter.
Fluxion delivers advanced solutions that automate complex cell-based and cell-free assays. Products include ERASE-Seq for NGS analysis of cancer from a “liquid biopsy” blood sample, IsoFlux for circulating tumor cell analysis, BioFlux for functional analysis of cellular interactions and the IonFlux automated patch clamp system.
Cell Microsystems provides pioneering solutions for cell biology research, and its lead products, the CellRaft AIR® System and CellRaft® Arrays, enable workflows to be performed on a single consumable. This includes clonal propagation of single cells for CRISPR gene editing, cell line development, stem cell studies, organoids and other 3D cultures, cell-based assays and genomics research.
The financial terms of the acquisition were not disclosed.
